Impax Laboratories (IPXL) Misses Q2 EPS by 11c; Guides Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- Arm Holdings falls as CFO stock sale weighs on sentiment
RBC Capital Cuts Price Target on Impax Laboratories (IPXL) Following Unexpected 2Q Miss
August 10, 2016 7:39 AM EDTRBC Capital maintained a Sector Perform rating on Impax Laboratories (NASDAQ: IPXL), and cut the price target to $30.00 (from $35.00), following the company's 2Q earnings report. RBC updated IPXL's model with new 2016-18 EPS estimates of $1.58, $2.24 and $2.46.
Analyst Randall Stanicky commented,... More
Impax Laboratories (IPXL) PT Cut to $24 at Leerink Partners
August 10, 2016 7:08 AM EDTLeerink Partners analyst Jason Gerberry cut his price target on Impax Laboratories (NASDAQ: IPXL) to $24.00 (from $33.00) following a big Q2 miss and "questionable" guidance. The firm maintained a Market Perform rating.
Gerberry commented, "In 2Q, IPXL missed consensus sales and EPS by 25% and 54%, respectively.... More
